M
M. Namjoshi
Researcher at Eli Lilly and Company
Publications - 18
Citations - 715
M. Namjoshi is an academic researcher from Eli Lilly and Company. The author has contributed to research in topics: Olanzapine & Bipolar disorder. The author has an hindex of 10, co-authored 17 publications receiving 704 citations. Previous affiliations of M. Namjoshi include Harvard University.
Papers
More filters
Journal ArticleDOI
A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania.
Mauricio Tohen,Mauricio Tohen,Joseph F. Goldberg,Ana Maria Gonzalez-Pinto Arrillaga,Jean M. Azorin,Eduard Vieta,Marie Christine Hardy-Bayle,William Lawson,Robin Emsley,Fan Zhang,Robert W. Baker,R.C. Risser,M. Namjoshi,Angela R. Evans,Alan Breier +14 more
TL;DR: The data suggest that olanzapine does not differ from haloperidol in achieving overall remission of bipolar mania, however, hal operidol carries a higher rate of extrapyramidal symptoms, whereas olanZapine is associated with weight gain.
Journal ArticleDOI
Long-term olanzapine therapy in the treatment of bipolar I disorder: an open-label continuation phase study
TL;DR: During up to 1 year of olanzapine therapy, either as monotherapy or in combination with lithium and/or fluoxetine, patients with bipolar disorder demonstrated significant improvement in mania and depression symptoms with a favorable safety profile.
Journal ArticleDOI
A review of the health-related quality of life literature in bipolar disorder
M. Namjoshi,Don P. Buesching +1 more
TL;DR: In the absence of a disease-targeted measure, a combination of the SF-36 and the PGWB is presently recommended as the battery of choice to assess the health-related quality of life of individuals with bipolar disorder.
Journal ArticleDOI
Olanzapine versus haloperidol in the treatment of acute mania: clinical outcomes, health-related quality of life and work status.
Lizheng Shi,M. Namjoshi,Fan Zhang,G. Gandhi,Eric T. Edgell,Mauricio Tohen,Alan Breier,J. M. Haro +7 more
TL;DR: Compared to haloperidol, olanzapine treatment was comparably effective in the remission of bipolar mania and significantly improved HRQOL and work status in patients with bipolar I disorder.
Journal ArticleDOI
Effects of olanzapine alone and olanzapine/fluoxetine combination on health-related quality of life in patients with bipolar depression: secondary analyses of a double-blind, placebo-controlled, randomized clinical trial.
Lizheng Shi,M. Namjoshi,Ralph Swindle,Ralph Swindle,Xiaomin Yu,R.C. Risser,Robert W. Baker,Mauricio Tohen,Mauricio Tohen +8 more
TL;DR: Based on these analyses, patients with bipolar depression receiving olanzapine or OFC for 8 weeks had greater improvement in HRQOL than those receiving placebo, and correlation results support the construct validity of the QLDS.